Actifuse Flow, Baxter International’s new synthetic bone graft surrogate from its osteobiologics surgery series, wins FDA approval for implementation in orthopedic surgeries.

In order to reach tine bony cracks and gaps of the skeletal structure, the new bone graft alternative is designed to reach these exact cranny locations. It is delivered via a syringe already containing it to speed-up bone growth. No preparatory procedure or mixing is needed to use this bone graft substitute and it maintains its fluid consistency during the surgery.

The surgical products manufacturer’s Actifuse Bone Graft Alternative constituting Actifuse Flow implements the silicate-substituted technology for bone formation via raised levels of silicon.

It becomes an ideal candidate for minimally invasive surgical procedures as the syringe facilitates the start and stop of flow to deliver the precise amount of substance. This also enables it to compact small done deformities as well as the intricate disorder of bone structure.

Additionally, when the bone is healing, the natural bone replaces this graft substitute as it gets reabsorbed, making it suitable for orthopedic surgeries on the posterolateral spine, extremities and the pelvis.

Baxter Advanced Surgery business president Wil Boren said, “As part of our growing product portfolio, Actifuse Flow builds on the extensive clinical experience of our Actifuse Bone Graft Substitute. We strive to pioneer products that provide surgeons with innovative and dependable tools to help enhance healing, improve outcomes and reduce the total cost of care.”

The Actifuse Flow will be available in the market in 1.5ml, 3ml and 5ml sizes in the upcoming months.